Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Central Mechanisms and Treatment Response of Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor
NCT03292458Phase 3Completed
- Start
- Jan 2018
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sodium oxybate in Spasmodic dysphonia (SD) and essential voice tremor (EVT) (2 arms). Primary endpoints: Symptom Severity and Minimum Treatment Efficacy. Started Jan 2018; status: completed.
02
Drugs
sodium oxybate
03
Conditions
Spasmodic dysphonia (SD)essential voice tremor (EVT)
Beyond the preview
Go deeper on NCT03292458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03292458.